Hoth TherapeuticsHOTH
Market Cap: $7.32M
About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Employees: 3
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
10% more funds holding
Funds holding: 10 [Q1] → 11 (+1) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5.07% less ownership
Funds ownership: 11.57% [Q1] → 6.51% (-5.07%) [Q2]
58% less capital invested
Capital invested by funds: $765K [Q1] → $317K (-$447K) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 372%upside $5 | Buy Maintained | 5 Sept 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 372%upside $5 | Buy Assumed | 21 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 277%upside $4 | Buy Reiterated | 16 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 277%upside $4 | Buy Reiterated | 26 Jul 2024 |
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 277%upside $4 | Buy Reiterated | 22 Jul 2024 |
Financial journalist opinion
Based on 4 articles about HOTH published over the past 30 days